Overcoming B16F10 Melanoma by Local Co-Delivering Chemotherapeutics and Anti-Angiogenic Agents Using Injectable Thermoresponsive Polypeptide Hydrogels
ACS Applied Materials & Interfaces · 03.11.2026
DOI: 10.1021/acsami.6c15683 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, online erschienen am 03.11.2026. Verfasst von Ruonan Huang und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Polymer Science and Technology, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun130022, China. Hauptthemen laut MEDLINE: Hydrogels, Angiogenesis Inhibitors, Melanoma, Experimental, Peptides. Die Arbeit nennt 75 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Changchun Science and Technology Bureau, Department of Science and Technology of Jilin Province.
Abstract (Originalsprache)
The immunosuppressive tumor microenvironment, along with the vascular barrier within B16F10 melanoma, frequently compromises the therapeutic outcomes of antitumor immunotherapy. Hydrogels, possessing three-dimensional network structures, provide a platform for localized drug delivery. Herein, we reported a thermoresponsive polypeptide hydrogel co-loaded with mitoxantrone (MTX) and the angiogenesis inhibitor nintedanib (NE), combined with immune checkpoint blockade therapy, to address these challenges. Results demonstrated that the release of MTX induced immunogenic cell death of tumor cells and released tumor-associated antigens, while the release of NE inhibited angiogenesis, promoted drug permeation and immune cell infiltration, enhanced therapeutic efficacy, and suppressed tumor proliferation and metastasis. In a melanoma-bearing mouse model, the combination of intratumoral injection of MTX/NE-loaded hydrogel with intravenous injection of anti-PD-1 elicited a strong systemic anti-tumor immune response, successfully inhibiting tumor growth and metastasis, while prolonging animal survival. Overall, this study established a hydrogel drug delivery strategy to overcome B16F10 melanoma, demonstrating strong potential in clinical cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Polymer Science and Technology, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun130022, China.
- School of Applied Chemistry and Engineering, University of Science and Technology of China, Hefei230026, China.
ORCID-Profile: Yan Rong, Chaoliang He
Förderung
- National Natural Science Foundation of China
- Changchun Science and Technology Bureau
- Department of Science and Technology of Jilin Province
Zitieren
APA
Huang, R., Wu, Y., Yang, J., Li, F., Cheng, Q., Qi, D., Rong, Y., & He, C. (2026). Overcoming B16F10 Melanoma by Local Co-Delivering Chemotherapeutics and Anti-Angiogenic Agents Using Injectable Thermoresponsive Polypeptide Hydrogels. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.6c15683
Vancouver
Huang R, Wu Y, Yang J, Li F, Cheng Q, Qi D, et al. Overcoming B16F10 Melanoma by Local Co-Delivering Chemotherapeutics and Anti-Angiogenic Agents Using Injectable Thermoresponsive Polypeptide Hydrogels. ACS Applied Materials & Interfaces. 2026. doi:10.1021/acsami.6c15683
BibTeX
@article{Huang2026,
author = {Huang, Ruonan and Wu, Yijun and Yang, Jiaxuan and Li, Fujiang and Cheng, Qian and Qi, Desheng and Rong, Yan and He, Chaoliang},
title = {Overcoming B16F10 Melanoma by Local Co-Delivering Chemotherapeutics and Anti-Angiogenic Agents Using Injectable Thermoresponsive Polypeptide Hydrogels},
journal = {ACS Applied Materials & Interfaces},
year = {2026},
doi = {10.1021/acsami.6c15683}
}
EUVIMED